STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

Home・Akcijų sąrašas・GlaxoSmithKline PLC

GlaxoSmithKline PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

1,846.25 0.29

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1841

Max

1869.25

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.2B 1.8B
Pardavimai	-989M 7.6B
P/E Sektoriaus vid.	13.387 49.8
Pelnas, tenkantis vienai akcijai	0.465
Dividendų pajamingumas	3.47
Pelno marža	24.105
Darbuotojai	66,841
EBITDA	577M 2.8B

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+7.24% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	3.47% 2.25%
Kitas uždarbis	2026-07-29
Kitas dividendų mokėjimo data	2026-07-09
Kita Ex Dividend data	2026-05-14

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.2B 76B
Ankstesnė atidarymo kaina	1845.96
Ankstesnė uždarymo kaina	1846.25

Naujienos nuotaikos

By Acuity

56%

44%

271 / 347 reitingas Healthcare

GlaxoSmithKline PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 06:42; UTC

Uždarbis

GSK Earnings Boosted by Higher Specialty Medicine Sales

2026-05-06 13:35; UTC

Rinkos pokalbiai

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

2026-04-29 10:39; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

2026-04-29 10:06; UTC

Rinkos pokalbiai

Uždarbis

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

2026-04-29 10:02; UTC

Rinkos pokalbiai

Uždarbis

GSK Makes Ideal Start for New CEO -- Market Talk

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Sees 70p 2026 Dividend Payout

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Declares Dividend of 17p

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Free Cash Flow of GBP0.8B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC Cash Generated From Operations GBP1.4B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q General Medicines Sales GBP2.3B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q Vaccines Sales GBP2.1B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

2026-04-29 06:05; UTC

Uždarbis

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

2026-04-29 06:04; UTC

Uždarbis

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK PLC Core EPS of 43.3p

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

2026-04-29 06:04; UTC

Uždarbis

GSK PLC 1Q Adj EPS 46.50p

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Turnover Growth of 3%-5%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Backs 2026 View

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q EPS 42.6p

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Turnover GBP7.63B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Pretax Pft GBP2.14B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Oper Pft GBP2.29B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Net Pft GBP1.74B

2026-04-15 06:12; UTC

Įsigijimai, susijungimai, perėmimai

GSK Completes Acquisition of 35Pharma

2026-04-10 10:43; UTC

Rinkos pokalbiai

GSK Could Report Weak General Medicines Results -- Market Talk

2026-03-31 14:02; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics Will Continue Supplying Products Previously Manufactured at Site to GSK Under Terms of Agreement

Akcijų palyginimas

Kainos pokytis

GlaxoSmithKline PLC Prognozė

Kainos tikslas

By TipRanks

7.24% į viršų

12 mėnesių prognozė

Vidutinis 1,976.36 GBX 7.24%

Aukščiausias 2,630 GBX

Žemiausias 1,500 GBX

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines GlaxoSmithKline PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių GlaxoSmithKline PLC akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

271 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.